We are proud to announce a new partnership with @Boehringer to research and develop SZN-413 for treatment of retinal diseases. Learn more in today’s press release: bit.ly/3SZaCxV

#DiabeticRetinopathy is a serious public health issue & major cause of vision loss and disability. We're excited to publish preclinical data demonstrating the promise of SZN-413 in @ARVOtvst - learn more here: bit.ly/3R9z3aB #WntPathway #Biotech

Surrozen Reports Second Quarter 2022 Financial Results bit.ly/3Qkdapq

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis bit.ly/3mIGbOp

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW) bit.ly/3yTjfTU

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis bit.ly/3woBcZ3

Surrozen Reports First Quarter 2022 Financial Results bit.ly/3M5VETX

Today we announced our fourth quarter 2021 financial results and full year corporate updates: investors.surrozen.com/news-… $SRZN

“The success of every woman should be the inspiration to another. We should raise each other up. Make sure you’re very courageous: be strong, be extremely kind, and above all be humble.” – Serena Williams #womanshistorymonth #surrozen

A strong culture fuels the quality of our work experience and we are committed to strengthening our culture every day. We develop leaders at all levels, expand our comfort zones through team adventures and enthusiastically celebrate our accomplishments together.

We’re seeking scientists to join our efforts in discovering innovative drugs that accelerate the repair and renewal of human tissues. Click here for available jobs: surrozen.com/people/careers

Our breakthrough approach leverages the full therapeutic potential of the Wnt signaling pathway. Click here to learn more: surrozen.com/platform/wnt-bi…